Introduction
Quality improvement efforts during the past decade have translated into shorter times to reperfusion and greater myocardial salvage in patients with ST-segment elevation myocardial infarction (STEMI). 1 As a result, most patients surviving a STEMI today have a preserved or only moderately reduced left ventricular (LV) systolic function. 2, 3 However, patients with severe LV dysfunction continue to be at risk of adverse LV remodelling and heart failure. 4 Intracoronary infusion of autologous bone marrow cells (BMCs) has been explored as an adjunctive strategy to improve heart function and outcome after STEMI. 5 Some early clinical trials suggested that BMC therapy increases left ventricular ejection fraction (LVEF) after STEMI. [6] [7] [8] [9] More recent trials did not detect significant treatment effects of BMCs on LVEF, although secondary endpoints were improved in some of these later studies. [10] [11] [12] [13] [14] Lately, a review by the Cochrane Collaboration of 41 randomised-controlled trials found insufficient evidence for a beneficial effect of BMC therapy after myocardial infarction (MI). 15 We previously assessed the effect of intracoronary BMC infusion on LVEF recovery in the randomised-controlled BOne marrOw transfer to enhance ST-elevation infarct regeneration (BOOST) trial which included 30 BMC-treated patients and 30 control patients. 6 BOOST was an open-label study; patients in the control group received optimum post-infarction treatment but did not undergo bone marrow harvest and did not receive a placebo infusion. Unlike other trials that used only the mononucleated BMC fraction, [7] [8] [9] [10] [11] [12] [13] [14] all nucleated BMCs were infused in BOOST. 6 As a result, infused cell numbers were about one order of magnitude higher in BOOST than in the other cell therapy trials. [6] [7] [8] [9] [10] [11] [12] [13] [14] As shown by magnetic resonance imaging (MRI) and blinded image analyses, BMC therapy enhanced LVEF by 6 .0 percentage points after 6 months compared with the control group (P = 0.003). 6 This represented one of the largest effect sizes in any of the clinical trials, 15 although the difference in LVEF improvement between groups was no longer statistically significant after 18 months (2.8 percentage points, P = 0.27). 16 Preclinical studies have indicated that BMCs, and the lineagecommitted stem and progenitor cell populations that they contain, do not proliferate and differentiate into mature cardiac cell types after transplantation into the infarcted heart. 17 Instead, transcriptome and proteome analyses have shown that various bone marrowderived cell types release a broad repertoire of cytokines, chemokines, and growth factors that may promote tissue protection and repair in a paracrine manner, which does not require long-term cell engraftment. 18 Indeed, we previously found that nucleated BMCs prepared according to the BOOST protocol are a rich source of paracrine-acting proteins, 19 some of which promoted therapeutic effects in mice with experimentally-induced MI. 20 Clinical evidence for the paracrine concept of BMC therapy is lacking, however.
Here, we re-evaluated the therapeutic potential of nucleated BMCs in the randomised placebo-controlled, double-blind BOOST-2 trial. Using a multiple arm design, we investigated whether the effects of BMCs on LVEF are dose-dependent (or if similar effects can be achieved with a smaller bone marrow aspiration volume), and whether c-irradiation of BMCs has an impact on their therapeutic efficacy. c-irradiation of blood components is commonly used to mitotically inactivate T lymphocytes and prevent transfusionassociated graft vs. host disease, while preserving cellular activities not requiring intact DNA. 21 We reasoned that c-irradiation will eliminate the clonogenic and transdifferentiation potential of BMCs while retaining cell viability and paracrine function thereby enabling us to explore mechanisms of action in a clinical context (Supplementary material online, Figure) .
Methods
Please refer to the Supplementary material online for an extended Methods section, including power calculation and statistical analysis plan. BOOST-2 was a randomised placebo-controlled, double-blind trial investigating the effects of intracoronary BMC transfer on LV systolic function and remodelling in patients with STEMI and a reduced LVEF. Patients were recruited from 10 centres (Supplementary material online, Table  S1 ) and were randomly allocated to 6 groups in a 1:1:2:2:2:2 ratio:
-low-dose bone marrow harvest and placebo cell infusion (loPlacebo) -high-dose bone marrow harvest and placebo cell infusion (hiPlacebo) -low-dose bone marrow harvest and low-dose BMC infusion (loBMC) -high-dose bone marrow harvest and high-dose BMC infusion (hiBMC) -low-dose bone marrow harvest and low-dose irradiated BMC infusion (loBMCi) -high-dose bone marrow harvest and high-dose irradiated BMC infusion (hiBMCi)
The two placebo groups were combined in all analyses (control group). The hiBMC group was designed to match the BMC group in BOOST. Nucleated BMCs were prepared by gelatine-polysuccinate density gradient sedimentation using the original protocol from the BOOST trial. 6, 22 To prepare irradiated BMCs, the bone marrow sample was c-irradiated prior to the sedimentation process. The placebo product was prepared from a peripheral blood sample and designed as a pure red blood cell suspension that was indistinguishable from the BMC products in terms of Intracoronary autologous bone marrow cell transfer after myocardial infarction
packaging, labelling, volume, and appearance. Cell products were infused into the infarct-related artery via the central lumen of an over-the-wire balloon catheter (stop-flow technique). Contrast-enhanced cardiac MRI was performed in the study centres according to a standardised protocol. MRIs were read locally to assess patient eligibility for the trial. After completion of the trial, all MRIs were sent to the core lab in Stuttgart to assess the MRI endpoints. Change in LVEF from baseline to 6 months was the primary endpoint. Secondary MRI endpoints included changes in LV enddiastolic volume (LVEDV) index, LV end-systolic volume (LVESV) index, infarct volume, and regional systolic function.
Results

Baseline characteristics
Between 9 March 2006 and 16 July 2013, 217 patients were assessed for eligibility by MRI and 188 patients were randomly allocated to the 6 groups ( Figure 1) . Bone marrow was harvested in 175 patients who constitute the safety population. 172 patients were treated with cells (BMCs or placebo), 8 of whom declined the follow-up MRI. 2 patients died within 6 months after cell transfer. The follow-up MRI was technically not feasible in 1 patient who had received an implantable cardioverter defibrillator. The core lab excluded 8 additional patients from the analysis (6 patients with MRI scans that were of poor quality due to breathing or triggering artefacts, and 2 patients with no late contrast enhancement and a preserved LVEF on their baseline MRI scan), leaving 153 patients in the efficacy analysis population.
Patients in the efficacy analysis population were 55 ± 10 years old and predominantly male ( Table 1) . The median (inter-quartile range, IQR) time from symptom onset to PCI was 4.8 (2.9-9.1) h. 108 patients (71%) had an anterior STEMI with the LAD as the infarctrelated artery. 2 patients (1.3%) had received thrombolytic therapy before PCI; 63 patients (41%) received at least one drug-eluting stent. All patients received guideline-recommended post-infarction medical treatment ( Table 1) .
Cell products
Cells were harvested 7.1 ± 2.6 days after PCI ( Table 1) . The cell product in the hiBMC group had a volume of 36 ± 5 mL. The product contained 20.6 ± 7.7 Â 10 8 nucleated cells and 8.2 ± 5.3 Â 10 6 CD34 þ cells, and displayed in vitro colony-forming activity. Cell viability was 99 ± 1% ( Table 2) . The loBMC product contained approximately one-third of the nucleated and CD34 þ cells in the hiBMC product, but was comparable in terms of volume and haematocrit. c-irradiation abolished colony forming activity in the loBMCi and hiBMCi products but did not affect cell numbers, cell viability, and paracrine potential ( Table 2) . Figure 1 Participant flow. Patients were randomly allocated to 6 groups: low-dose bone marrow harvest with placebo cell infusion (loPlacebo), high-dose bone marrow harvest with placebo cell infusion (hiPlacebo), low-dose bone marrow cell infusion (loBMC), high-dose BMC infusion (hiBMC), low-dose irradiated BMC infusion (loBMCi), and high-dose irradiated BMC infusion (hiBMCi). *BMCs were not irradiated in 3 patients from the loBMCi group and in 1 patient from the hiBMCi group. These patients were assigned to the loBMC and hiBMC groups, respectively. (21) 1 (4) 3 (10) Killip class III, n (%)
17 (65) 30 (79) 23 (70) 17 (68) 21 (68) LCX, n (%)
7 (27) 7 (18) 7 (21) Table S2 ).
Primary endpoint
The baseline MRI was performed 4.4 ± 1.9 days after PCI ( Table 1) . In the overall efficacy analysis population, baseline LVEF was 45.0 ± 8.5%. LVEF increased to 48.8 ± 9.4% after 6 months, representing an improvement of 3.8 (95% confidence interval, 2.7 to 4.9) percentage points ( Table 3) . LVEF increased from baseline to 6 months by 3. 
Secondary endpoints
In the overall efficacy analysis population, LVEDV index increased by 3.6 (0.8 to 6.4) mL/m 2 from baseline to 6 months (P = 0.012), whereas LVESV index decreased by -0.7 (-3.0 to 1.6) mL/m 2 (P = 0.56) ( Table 4) . Infarct volume at baseline was 41.7 ± 21.1 mL and decreased by 11.8 (9.5 to 14.0) mL at 6 months (P < 0.001). Changes of LVEDV index, LVESV index, and infarct volume from baseline to 6 months did not differ significantly between the control and any of the four BMC groups ( Table 4) . Regional systolic function in the infarct region and the infarct border zone improved from baseline to 6 months in the overall efficacy analysis population, but no significant Table S3 ).
Subgroup analyses
We assessed the effect of hiBMC infusion on LVEF change from baseline to 6 months in prespecified subgroups defined according to age, time from symptom onset to PCI, baseline LVEF, infarct volume, and MVO volume and in exploratory subgroups defined according to stent type, time from PCI to cell transfer, and use of a mineralocorticoid receptor antagonist (Supplementary material online, Left ventricular end-diastolic volume (LVEDV), end-systolic volume (LVESV), and infarct volume at baseline and 6 months (means ± SD). Infarct volumes were determined in patients with a complete stack of evaluable short axis late enhancement slices. Changes from baseline to 6 months and treatment effects are expressed as differences in leastsquares means (ANCOVA model with adjustment for baseline values with 95% confidence intervals). loBMC, low-dose bone marrow cell (BMC) group; hiBMC, high-dose BMC group; loBMCi, low-dose irradiated BMC group; hiBMCi, high-dose irradiated BMC group. 
Safety of intracoronary cell transfer and clinical events during follow-up
Adverse events related to cell harvest were not observed in any patient. Cell infusions were well tolerated in all patients except four who developed intracoronary complications; the infusion was prematurely stopped in two of these patients (Supplementary material online, Table S5 ). All 4 patients fully recovered and are included in the efficacy analysis population. One patient developed a groin haematoma after cell infusion requiring a blood transfusion and surgical drainage. This patient refused to undergo MRI at 6 months and was excluded from the efficacy analysis population. No patient developed a procedure-related acute MI. During 6 months of follow-up, 2 patients died, 4 patients were hospitalised for heart failure, and 1 patient developed a recurrent MI (Supplementary material online, Table S6 ). Except for the 2 patients who died, these patients were included in the efficacy analysis population.
Discussion
Intracoronary infusion of nucleated BMCs enhanced the recovery of LVEF after STEMI in the BOOST trial. 6 We reassessed this therapeutic strategy in the randomised placebo-controlled, double-blind BOOST-2 trial. We explored the dose-response relationship and the importance of BMC clonogenic potential. Treatment with clonogenic or non-clonogenic BMCs did not improve LVEF or any secondary MRI endpoint in BOOST-2. BOOST-2 met several key criteria of a well-conducted phase-2 cell therapy trial. All possible logistic efforts were taken to blind patients, their treating physicians, and the MRI core lab to the cell product being used. To this end, all patients underwent bone marrow harvest and received an intracoronary infusion (BMCs or placebo). Cells were processed in two GMP-certified cell manufacturing facilities using the protocol from the BOOST trial. As intended, cell characteristics of the high-dose, non-irradiated BMC product were comparable to the BMC product in BOOST. c-irradiation abolished BMC colony forming potential but did not affect cell numbers, cell viability, and paracrine potential. LV systolic function was assessed by MRI, the preferable imaging modality for a comprehensive evaluation of systolic function and infarct morphology. 23 MRI analyses were performed in a core laboratory by investigators who were not involved in patient recruitment and follow-up. Statistical analyses were performed by an independent contract research organization. Because of differences in trial design and changing medical practice, BOOST-2 differed from BOOST in several aspects (Supplementary material online, Table S7 ). BOOST-2 included patients with more severely depressed LVEF and therefore a greater potential to benefit from additional therapies. 3 Due to restricted MRI availability in some centres, baseline MRI was performed somewhat later in BOOST-2 than in BOOST. Due to delayed MRI and involvement of two independent local teams, cells were harvested later in BOOST-2 than in BOOST.
Major changes in patient management have occurred during the time period in which the BOOST trials were conducted (primary PCI as the preferred revascularisation strategy, more frequent use of drug-eluting stents and mineralocorticoid receptor antagonists in BOOST-2 than in BOOST). Improved patient management may have contributed to the more pronounced recovery of LVEF in the control group in BOOST-2 compared with BOOST (on average 3.3 vs. 0.7 percentage points), and may have made it more difficult for BMC therapy to provide incremental benefit.
We do not know whether these differences in trial design and management contributed to the neutral result of the BOOST-2 trial. We detected no significant interactions between any of the above variables and hiBMC treatment effect. However, these subgroup analyses had limited statistical power due to small sample sizes. Notably, hiBMC therapy was associated with an improvement in LVEF in patients with little or no MVO; considering the interaction P value of 0.046 and that 8 subgroup analyses were performed this may be a spurious finding.
Our study has a number of limitations that merit consideration. First, patient enrolment was slower than expected. In the majority of patients screened for the trial, LVEF was only slightly reduced, a likely reflection of the increasingly shorter times to reperfusion in STEMI. 1 Other patients, who had a more severely depressed LVEF, could not be included because they were intubated or required mechanical circulatory support and could not undergo MRI, had had a previous MI, or had multivessel disease necessitating repeat coronary intervention. Similar to our experience, other multicentre cell therapy trials looking at MRI endpoints required 5 years or more to recruit between 100 and 200 patients, emphasizing the challenges of performing such trials in this patient population. 13, 14 Second, due to slow recruitment, the trial was stopped early with 153 instead of 200 evaluable patients. However, with a numerical hiBMC treatment effect of only 1.0 percentage points (P = 0.57) which was much smaller than the 6.0 percentage points in BOOST and the 5.5 percentage points used for sample size calculation, the reduced sample size cannot explain the neutral outcome of the trial. Third, our patient population developed only modest adverse LV remodelling and had a good prognosis 6 months after PCI with only 2 deaths and 4 heart failure hospitalizations. With current treatment strategies such patients may not benefit from additional therapies. Certainly, a further lowering of the LVEF inclusion criterion would have slowed patient recruitment even more. Of note, subgroup analyses did not provide a signal for greater treatment effects in patients with larger infarcts or more severely depressed LVEF. Finally, baseline LVEF was somewhat higher in the control group than in the BMC groups. However, all MRI endpoints were calculated based on ANCOVA models which were adjusted for baseline differences.
In conclusion, BOOST-2 does not support the use of nucleated BMCs in patients with STEMI and moderately reduced LVEF treated according to current standards of early PCI and drug therapy.
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Supplementary material is available at European Heart Journal online.
